Morphic Medical today announced positive findings from a study of its Reset device that targets the cause of obesity and type 2 diabetes.
Boston-based Morphic develops Reset, an incision-free, endoscopically delivered therapy for treating metabolic disorders. The duodenal-jejunal bypass liner (DJBL), implanted and removed endoscopically, remains in place for up to nine months. By creating a temporary barrier in the upper intestine, it can support significant weight loss and blod sugar control.
Morphic says the device enhances the natural gut hormone responses in a way similar to GLP-1 therapies. However, unlike gastric bypass surgery, it offers a minimally invasive, fully reversible option.
The new data for Reset comes from a global registry capturing real-world outcomes in 1,298 patients across 37 centers in 12 countries. Professor Ricardo Cohen, president of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), will present findings at the IFSO 2025 World Congress in Santiago, Chile.
Findings confirmed substantial and durable benefits with Reset, Morphic said. That includes an average of 18.9% total body weight lost. Blood sugar levels, as measured by HbA1c, fell by 1.3%, with the greatest improvements seen in patients starting at higher levels. The company saw durable benefits, with 77% of patients maintaining improvement three years after the removal of Reset.
Morphic said the new nine-month treatment approach delivers the benefits with fewer complications compared to a 12-month approach.
Reset already holds CE mark approval, with a rollout in Germany expected soon, along with potential UK approval.
“I am delighted by these results, which show that RESET delivers nearly 19% weight loss and meaningful improvements in blood sugar control,” said Mike Gutteridge, president & CEO of Morphic Medical. “Unlike drug-based therapies, these benefits have been shown to last for years even after treatment has ended. With outcomes achieved in just nine months and with fewer risks, RESET is becoming an increasingly important option for people living with obesity and type 2 diabetes, as well as for governments worldwide tackling these global epidemics.”
